UPDATE: Viscient Biosciences Offer For Organovo Shows Final Co., After Reverse Stock Split, Would Trade Under 'Viscient,' 'Most Like As A Stock In Price Range $4.50-$5.50,' With Market Cap $75M-$125M
Benzinga Newsdesk